89bio

89bio: Pegozafermin Could Be A Game-Changer For Liver Disease – Strong Buy (NASDAQ:ETNB)

admin May 23, 2024 0

mi-viri 89bio, Inc. (NASDAQ:ETNB) is a clinical-stage biopharmaceutical company based in San Francisco, California. The company focuses on developing therapies...

Healthcare utilization, mortality, and cardiovascular events following GLP1-RA initiation in chronic kidney disease

admin December 7, 2024 0

Patients with MAFLD have 4.7 times higher risk of developing liver cancer, study finds

admin December 5, 2024 0

Ulster University ‘research breakthrough’ in early diagnosis of chronic kidney disease and Covid

admin December 4, 2024 0

With A CAGR 6.6%, Acute Kidney Injury Treatment Market

admin December 3, 2024 0

How Alcohol Consumption and Antimicrobial Resistance Impact Liver Health

admin December 2, 2024 0